Employment of patients with AS compared with controls, by BASDAI

Slides:



Advertisements
Similar presentations
Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.
Advertisements

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.
The genomic region spanning rs shows enhancer activity.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Multivariable model of abatacept retention by RF and anti-CCP status in biologic-naïve patients with or without radiographic erosion at baseline. Multivariable.
Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Association of disease parameters at the time of methotrexate reinitiation during the OLE based on propensity score matching. Association of disease parameters.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Frequency of patients in flare at each time point over 3 months
Schematic presentation of enrichment through linkages of clinical Rheumatology register data to other national data sources within each of the five Nordic.
Univariate predictors of (A) ASDAS ID (<1
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.
Ratings of core domains stratified by stakeholder group in the second Delphi round. Ratings of core domains stratified by stakeholder group in the second.
(A) HLA-E expression on the surface of CD14+ cells in patients with AS, HLA-B*2705, HLA-B*2709-positive and HLA-B27-negative HCs. Results are expressed.
Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.
Factors influencing the relationship between disease activity (as measured with the ASDAS) and radiographic progression (as measured with the 2-year mSASSS.
Serum levels of (A), human β defensin-2 (hBD-2) and (B), lipocalin-2 (LCN-2) in active full-blown ankylosing spondylitis (AS, n=21) versus healthy controls.
(A) Reduction of circulating stromal cell-derived factor (SDF)-1 levels over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis.
Relationships between the baseline disease activity scores and scintigraphic sum scores for the patients with RA, pSpA and axSpA. Relationships between.
Probability plots JSN score at baseline (A), 10 years (B) and progression (C) for the different age groups (darkest dots: group
Different scenarios that explain the effect that an external factor (here occupational activity—blue collar vs white collar—used as an example) could hypothetically.
The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.
Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.
Difference in the risk of MACEs in patients treated with anti–IL17 agents compared with the placebo in RCTs. IL,interleukin; MACEs, major adverse cardiovascular.
Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.
Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.
Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.
Clinical response in patients with early and established RA at month 24. *p
Least squares mean (LSM) changes from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Total score and (B) Ankylosing.
Relative impact of the different levels of education on the physical and mental components of SF-12 across the different chronic disorders. Relative impact.
Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,
Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.
Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.
ACR20/50/70 response rates at week 24 (TP1 per-protocol set).
Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI
Characteristics of the included trials on non-pharmacological treatment. Characteristics of the included trials on non-pharmacological treatment. ASDAS,
Serum sRANKL and OPG levels in healthy donors and patients with RA at baseline and after MTX and low-dose prednisolone treatment. Serum sRANKL and OPG.
Monthly improvements in home productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (last observation.
Frequency of methotrexate (MTX) doses at 24 months (plot) and summary of MTX doses across the MTX dosing categories (low, medium, high) based on data at.
Meta-analysis of risk ratios for percentage of patients who developed catheter-associated urinary tract infection, for intervention versus control groups,
Subject disposition through week 156 of treatment
Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,
Difference in the risk of MACEs in patients treated with anti-TNF agents compared with the placebo in RCTs. MACEs, major adverse cardiovascular events;
Satisfaction with control of RA
The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.
The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day.
Associations of VO2peak to significant predictors.
Classification tree with the selected characteristics.
Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.
(A) NKG2A and (B) NKG2C expression on NK cells in subjects with AS and HCs. The upper figure represents % of NK positive cells; the lower figure represents.
Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.
Forest plot showing the results of the meta-analysis on the effect of strength exercise on M.quadriceps femoris in people with rheumatoid arthritis and.
Forest plot showing the results of the meta-analysis on the effect of aerobic exercise on measured on VO2max in people with rheumatoid arthritis, spondyloarthritis.
Multivariable model of adjusted
Graphical representation of the content of the Social Role Participation Questionnaire (SRPQ), which assesses several dimensions of role participation.
Percent of patients with ASDAS inactive disease grouped by normal or elevated CRP at baseline through week 156. §p
Improvement in BASDAI score in patients with normal or elevated CRP at baseline through week 156. *p
Odds ratio (95% confidence intervals) of reporting respiratory symptoms in patients with treated hypothyroidism or inflammatory bowel disease (IBD) compared.
Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.
Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.
Determinants of moderate Cardiovascular Health Index Score (achieving three or more risk factor targets), stratified by region conventions as in figure.
NRDC and TNF-α increase in synovial fluid from patients with RA
Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)
Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.
Distribution of points (%) across the ESSDAI domains in patients with neurological involvement and in those with non-neurological systemic involvement.
Presentation transcript:

Employment of patients with AS compared with controls, by BASDAI Employment of patients with AS compared with controls, by BASDAI. SERs with 95% CIs of patients with AS with controls set as reference (dotted line), stratified by symptom duration and BASDAI. Due to missing data, 203 (of 214) patients were included in this analysis. *P<0.05 compared to controls. AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; SERs, standardised employment ratios. . Employment of patients with AS compared with controls, by BASDAI. SERs with 95% CIs of patients with AS with controls set as reference (dotted line), stratified by symptom duration and BASDAI. Due to missing data, 203 (of 214) patients were included in this analysis. *P<0.05 compared to controls. AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; SERs, standardised employment ratios. Casper Webers et al. RMD Open 2018;4:e000680 Copyright © BMJ Publishing Group & EULAR. All rights reserved.